心房顫動手術市場-增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1189880

心房顫動手術市場-增長、趨勢、COVID-19 影響和預測 (2023-2028)

Atrial Fibrillation Surgery Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內(2022-2027 年),房顫手術市場預計將以 12.2% 左右的複合年增長率增長。

在COVID-19中,心血管疾病患者處於高危狀態,最有可能出現心肌炎、節律紊亂等多器官功能衰竭。 來自中國武漢的數據顯示,心律失常和急性心肌損傷是 COVID-19 確診陽性病例中最常見的心臟並發症。 此外,在 2020 年 2 月發表在美國醫學會雜誌 (JAMA) 上的病例報告中,休克 (8.7%)、急性呼吸窘迫綜合徵 (19.6%)、心律失常 (16.7%) 和急性心肌損傷 (17.2%)已經確認。 與在 ICU 外接受治療的患者相比,在 ICU 接受治療的患者也更容易出現其中一種並發症。

此外,由於 COVID-19 不斷演變的公共衛生危機,遠程監控使臨床醫生能夠在需要時與醫療保健專業人員和患者保持關係。 醫療保健提供者可以在患者在家時遠程訪問患者的健康信息,從而減少去醫院就診的需要並將暴露於 COVID-19 的風險降至最低。 需要開發新技術和數字平台來支持遠程醫療,還需要進一步研究遠程醫療、持續數據收集、先進車輛能力和遠程患者監控的作用,以指導最佳實踐。是的,並可能推動增長研究目標市場。

房顫市場受到全球肥胖和心髒病患病率上升的推動。 此外,心髒病是全世界死亡的主要原因之一,生活方式的改變正在迅速增加患有心髒病的人數。

此外,新產品不斷推向市場,進一步推動了市場增長。 例如,2022 年 4 月,AtriCure, Inc. 在美國推出了 EnCompass Clamp,這是 Isolator Synergy Ablation System 的一部分。 EnCompass 鉗具有 FDA 510(k) 心臟手術期間心臟組織消融許可,旨在使同步手術消融更有效。

此外,突顯心房顫動市場進步的不斷增加的研發程序也將提振市場。 例如,2022 年 1 月,Peerbridge Health 與 Northwell Health 合作推出了新的 AFib 卓越中心,這是一項旨在優化心房顫動 (AFib) 患者護理的多學科工作。 在 Peerbridge 的支持下,Northwell 的 AFib 卓越中心將開展一項試點計劃,重點關注未確診阻塞性睡眠呼吸暫停 (OSA) 的 AFib 患者。 該試點項目將幫助心髒病學和睡眠醫學醫師更好地了解這兩種疾病之間的重要聯繫,以及如何最好地同時快速有效地治療心房顫動和 OSA。旨在 因此,房顫藥物的進步有望推動市場。

因此,由於上述因素,市場有望在預測期內增長。 然而,與這些設備相關的高治療成本和監管問題預計會阻礙市場增長。

主要市場趨勢

門診手術中心部分預計在預測期內有良好的增長

由於強大的醫療保健基礎設施、熟練勞動力的可用性和負擔能力,預計門診手術中心部分將實現良好增長。 此外,預計該市場將受到患有動脈硬化和心力衰竭等生活方式相關疾病的患者數量增加以及老年人口增加的推動。 然而,與傳統手術相比,微創手術的優勢最終將導致細分市場的增長。 手術疼痛、受傷、住院時間更短、準確性更高和恢復時間更快等優勢正在促使患者選擇微創手術,這有望推動市場增長。

多種服務的增加以及門診手術中心的進步將進一步推動市場增長。 例如,2021 年 1 月,HST Pathways 推出了“HST One”,這是門診手術中心 (ASC) 的首要會員計劃。 該會員計劃將允許最終用戶選擇捆綁的流行產品作為其會員資格的一部分,並可以根據需要靈活地添加服務。 以這種方式在門診手術中心提供定制服務有望吸引更多患者並顯著擴大市場。

另外,隨著肥胖的增加,患心房顫動的人數也在增加。 因此,肥胖的增加被認為有助於市場增長。

此外,在 2022 年 4 月發表的論文“傳統非臥床和獨立門診設置中心房顫動的導管消融後當天出院”中,接受導管消融治療 AF 的患者的圍手術期管理已被證明類似於接受門診手術的患者。 因此,門診手術中心在促進房顫手術方面的進步將促進該領域的增長。

因此,由於上述因素,預計研究部門將對市場增長做出重大貢獻。

北美將是預測期內的主要增長部分

預計北美地區將主導房顫市場。 這主要是由於患者數量的增加和該地區大公司的存在。 北美地區的美國預計將主導市場增長。 根據CDC(美國疾病控制與預防中心)提供的統計數據,2021年9月,預計2030年美國將有1210萬人患房顫,未來有望增長。

由於主要參與者在該國的存在,技術進步和優惠保險政策的可用性促進了美國研究市場的增長。 例如,2020 年 7 月,波士頓科學公司推出了 WATCHMAN FLX 左,用於降低需要口服抗凝治療替代治療的非瓣膜性心房顫動 (NVAF) 患者的中風風險。獲得美國食品和藥物管理局批准用於心耳閉合 (LAAC) 裝置。

同樣在 2022 年 2 月,美敦力公司獲得了美國食品和藥物管理局批准的 Freezor 和 Freezor Xtra 心臟冷凍消融聚焦導管,用於治療增加的小兒房室折返性心動過速 (AVNRT) 我得到

此外,證明現有產品功效的研發在該地區很活躍,從而促進了這些產品的採用並推動了市場發展。 例如,2022年4月,CathVision宣佈在佛蒙特大學醫學中心完成CathVision ECGenius系統臨床評估試驗的患者入組。 ECGenius 代表了 ECG 信號採集、解釋和治療支持質量的重大進步,有助於正確診斷和設計複雜心律失常(包括心房顫動 (AF))的消融策略。

因此,由於上述因素,所研究的市場預計在研究期間會在同一地區增長。

競爭格局

這個市場分散且競爭激烈。 房顫市場由專注於開發新產品發布和見證新進入者市場滲透的本地和全球參與者組成。 技術進步和對改善醫療保健系統的關注可能會影響更多公司進入市場,從而進一步推動未來的市場增長。 市場上的主要參與者是波士頓科學公司、美敦力公司、Biotronik、AtriCure Inc.、Cardiofocus Inc.等。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 肥胖和日益加重的心髒病負擔
    • 提高公眾意識的計劃數量增加
  • 市場製約因素
    • 手術費用高
    • 與設備相關的監管問題
  • 五力分析分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:單位:百萬美元)

  • 按產品分類
    • 導管消融
    • 外科消融
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會國家
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Boston Scientific Corporation
    • Medtronic PLC
    • Biotronik SE & Co. KG
    • AtriCure Inc.
    • Cardiofocus Inc.
    • Abbott Laboratories
    • Johnson & Johnson
    • MicroPort Scientific Corporation
    • Koninklijke Philips NV
    • Siemens AG
    • Osypka AG
    • Kardium Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 67135

The Atrial Fibrillation Surgery Market is expected to register a CAGR of nearly 12.2% during the forecast period (2022-2027).

COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.

Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimize the risk of exposure to COVID-19. New technologies and digital platforms to aid in remote care should be developed, and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the studied market.

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.

Additionally, the launch of new products in the market will further boost the market growth. For instance, in April 2022, AtriCure, Inc. launched the EnCompass Clamp, a part of the Isolator Synergy Ablation System in United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.

Furthermore, the rising research and development procedures highlighting the advancements in the Atrial fibrillation market will also boost the market. For instance, in January 2022, Peerbridge Health collaborated with Northwell Health on their newly launched AFib Center of Excellence, a multi-disciplinary effort that optimizes treatment for patients with atrial fibrillation (AFib). With Peerbridge's support, Northwell's AFib Center of Excellence will conduct a pilot program focusing on AFib patients with undiagnosed obstructive sleep apnea (OSA). The pilot aims to help cardiology and sleep physicians better understand the critical link between the two conditions and how best to quickly and effectively treat AFib and OSA concurrently. Thus, advancements in atrial fibrillation therapeutics are expected to drive the market.

Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period. However, the high cost of procedures and regulatory issues associated with these devices is expected to hinder the market growth.

Key Market Trends

The Ambulatory Surgical Center Segment is Expected to Witness Good Growth over the Forecast Period

The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.

The addition of multiple services in advancing ambulatory surgical centers will further drive the market growth. For instance, in January 2021, HST Pathways launched a premier membership program for ambulatory surgery centers (ASCs), "HST One." This membership program will enable its end-user to select bundled popular products as part of their membership, with the flexibility to add additional services as needed. Such initiation of delivering customized services at ambulatory surgical centers will attract a greater number of patients and will lead to significant growth of the market.

In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.

Furthermore, the article "Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in Traditional Nonambulatory and Freestanding Ambulatory Settings" published in April 2022, the periprocedural management of patients who receive catheter ablation for AF is similar to those undergoing ambulatory surgery. Thus, such advancements in ambulatory surgical centers for the smooth transition of atrial fibrillation surgeries will drive the segment growth.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute significantly to market growth.

North America is the Major Growing Segment Over the Forecast Period

The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. United States within the North American region is expected to dominate the market growth. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in September 2021, it is estimated that 12.1 million people in United States will have atrial fibrillation in 2030, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future.

With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in United States. For instance, in July 2020, Boston Scientific Corporation received United States Food and Drug Administration approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.

Additionally, in February 2022, Medtronic plc received United States Food and Drug Administration approval for Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).

Furthermore, growing research and development for proving the efficacies of existing products in the region will increase their adoption, thereby driving the market. For instance, in April 2022, CathVision reported the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center. ECGenius represents an important evolution in the quality of ECG signal acquisition, interpretation, and therapy support which help in correctly diagnosing and devising ablation strategies for complex arrhythmias, including atrial fibrillation (AF).

Thus, due to the above-mentioned factors, the studied market is expected to grow in the region during the study period.

Competitive Landscape

The studied market is fragmented and moderately competitive. The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing the penetration of new entrants in the market. Technological advancements and the focus on improving the healthcare system are expected to influence more companies to enter the market, further driving market growth in the future. Major key players in the market include Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure Inc., and Cardiofocus Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Obesity and Heart Diseases
    • 4.2.2 Rising Number of Programs to Enhance Public Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Procedure
    • 4.3.2 Regulatory Issues Associated with the Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Catheter Ablation
    • 5.1.2 Surgical Ablation
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Medtronic PLC
    • 6.1.3 Biotronik SE & Co. KG
    • 6.1.4 AtriCure Inc.
    • 6.1.5 Cardiofocus Inc.
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Johnson & Johnson
    • 6.1.8 MicroPort Scientific Corporation
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Siemens AG
    • 6.1.11 Osypka AG
    • 6.1.12 Kardium Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS